Sino Biopharmaceutical Limited has announced that its innovative drug, TQC3721 inhalation suspension, a PDE3/4 inhibitor, has received approval from the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China to commence a phase III registrational clinical study. This study aims to explore the maintenance treatment for chronic obstructive pulmonary disease (COPD). TQC3721, known for its bronchodilatory and anti-inflammatory effects, is noted for its advanced research and development progress, ranking second worldwide. This phase III trial will include patients with dual bronchodilators as part of their background treatment, broadening its scope to cover a wider range of COPD patients. Additionally, an inhaled dry powder formulation of TQC3721 is in phase I clinical development, expected to enhance patient compliance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。